Exact Sciences Corporation
EXAS
$104.91
+0.95%
Exact Sciences Corporation is a healthcare company specializing in cancer screening and diagnostic test products. It is a leader in non-invasive cancer diagnostics, with core advantages in its proprietary Cologuard and Oncotype DX test platforms.
EXAS
Exact Sciences Corporation
$104.91
Related headlines
Investment Opinion: Should I buy EXAS Today?
Based on a synthesis of the data, the objective assessment for EXAS is Hold. The investment case is bifurcated: the fundamental operational story is strengthening with impressive revenue growth and cash flow, but the valuation has surged ahead of these improvements, leaving limited margin for error. The stock appears to be fairly valued at current levels, discounting much of the near-term positive momentum. New money may find better entry points on potential pullbacks, while existing holders have reason to maintain positions given the improving fundamentals.
Sign up to view all
EXAS 12-Month Price Forecast
The analysis leans neutral due to the conflict between strong fundamental improvements and a valuation that appears to have fully priced them in. Confidence is medium as the near-term direction is highly dependent on whether the company can exceed the high expectations embedded in the current stock price.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Exact Sciences Corporation's 12-month outlook, with a consensus price target around $136.38 and implied upside of +30.0% versus the current price.
Average Target
$136.38
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$84 - $136
Analyst target range
No sufficient analyst coverage available. The provided data includes recent rating downgrades from several firms (e.g., Mizuho to Neutral, Evercore ISI to In Line) in late 2025 and early 2026, but does not contain a consensus target price or ratings distribution. The focus appears to be on recent analyst actions rather than a consolidated summary of targets.
Bulls vs Bears: EXAS Investment Factors
Exact Sciences presents a classic high-growth, high-expectation investment case. The bull thesis is powered by exceptional revenue growth, rapid margin improvement, and strong cash generation. The bear case highlights persistent unprofitability, a premium valuation, and a stock price that has already discounted much of the near-term good news after a near-100% run.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 23.1% YoY, indicating robust demand for core products.
- Significant Profitability Improvement: Net loss narrowed dramatically from -$864.6M to -$86.0M YoY in Q4.
- Positive Free Cash Flow: Generated $356.8M TTM FCF, providing financial flexibility for growth.
- Market Leadership in Niche: Leader in non-invasive cancer diagnostics with Cologuard and Oncotype DX.
Bearish
- Persistent Unprofitability: Negative EPS, ROE, and ROA; company still not GAAP profitable.
- Premium Valuation Multiples: PS ratio of 5.9 and forward P/E of 55.2 imply high growth expectations.
- At Technical Resistance: Trading at 52-week high, suggesting limited near-term upside potential.
- High Leverage and Beta: Debt-to-equity of 1.05 and beta of 1.44 indicate higher financial and market risk.
EXAS Technical Analysis
The stock has exhibited an exceptionally strong uptrend over the past six months, rising approximately 96.8% from a price near $53.56 in late September 2025 to over $104 by March 2026. This surge was particularly pronounced in late November 2025, where the price jumped from around $69 to over $100 in a matter of days. Short-term performance shows consolidation at elevated levels. The stock gained 1.5% over the past month and 3.0% over the past three months, significantly outperforming the broader market, which declined 5.25% and 4.63% over the same periods, respectively. The current price of $104.91 is near the top of its 52-week range of $38.81 to $104.98, trading just 0.07% below the yearly high. This indicates the stock is at a technically strong resistance level after its massive rally.
Beta
1.44
1.44x market volatility
Max Drawdown
-29.6%
Largest decline past year
52-Week Range
$39-$105
Price range past year
Annual Return
+136.9%
Cumulative gain past year
| Period | EXAS Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | -4.3% |
| 3m | +3.0% | -4.0% |
| 6m | +96.8% | -2.0% |
| 1y | +136.9% | +22.2% |
| ytd | +3.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EXAS Fundamental Analysis
Revenue growth has been robust, with Q4 2025 revenue of $878.4 million representing a 23.1% year-over-year increase. However, profitability remains inconsistent; the company reported a net loss of $85.96 million in Q4 2025, though this is a significant improvement from the massive $864.6 million loss in Q4 2024. The gross margin remains healthy at approximately 70%. Financial health shows a debt-to-equity ratio of 1.05, indicating a moderate level of leverage. The company maintains a strong current ratio of 2.43 and generated positive free cash flow of $356.8 million over the trailing twelve months, providing operational flexibility. Operational efficiency metrics are mixed. Return on Equity (ROE) is negative at -8.66%, and Return on Assets (ROA) is -1.59%, reflecting the company's current lack of profitability. The negative EPS of -$0.011 underscores ongoing challenges in translating top-line growth to the bottom line.
Quarterly Revenue
$878381000.0B
2025-12
Revenue YoY Growth
+0.23%
YoY Comparison
Gross Margin
+0.70%
Latest Quarter
Free Cash Flow
$356782000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EXAS Overvalued?
Given the company's negative net income and negative EBITDA, the Price-to-Sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 5.90, and the Enterprise Value-to-Sales (EV/Sales) ratio is 6.65. These multiples reflect a premium valuation based on the company's high revenue growth profile. Peer comparison data is not available in the provided inputs. The valuation is primarily driven by growth expectations rather than current earnings, as evidenced by a forward P/E of 55.2 based on estimated future profitability.
PE
-92.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -2118x~3880x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
169.2x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation. The stock trades at a PS ratio of 5.9 and a forward P/E of 55.2, pricing in near-perfect execution of future growth and a swift path to sustained profitability. Any stumble in revenue growth or a delay in reaching profitability could lead to a significant multiple contraction. The high beta of 1.44 also means the stock is likely to be more volatile than the broader market, especially in a risk-off environment. Operational and financial risks include the company's ongoing net losses and negative return metrics (ROE: -8.7%, ROA: -1.6%). While improving, profitability is not yet assured. The moderate debt load (D/E: 1.05) is manageable given the positive FCF, but it adds fixed costs through interest expense. Competitive and regulatory risks are inherent in the healthcare diagnostics sector, where reimbursement rates and market adoption are critical. Finally, technical and sentiment risks are elevated. The stock is at its 52-week high after a parabolic rise, making it susceptible to profit-taking. Recent analyst downgrades to neutral stances reflect this caution. The news snippet about a potential acquisition by Abbott, while unconfirmed in other data, adds an event risk that could lead to heightened volatility.
FAQ
The key risks are: 1) Valuation Risk: High multiples (PS 5.9) could contract if growth slows. 2) Profitability Risk: The company is still not GAAP profitable (negative EPS). 3) Technical Risk: The stock is at a 52-week high after a massive rally, making it prone to profit-taking. 4) Market Risk: With a beta of 1.44, it is more volatile than the market. 5) Execution Risk: Future growth depends on successful product adoption and pipeline development.
The 12-month outlook is for consolidation with a neutral bias. The base case (55% probability) sees a trading range of $95-$110 as the stock digests its massive gains and valuation normalizes. A bull case (25%) to $130+ requires exceeding high growth/profitability expectations. A bear case (20%) could see a pullback towards $70 if execution falters or the market sours on high-multiple stocks. The forward P/E of 55.2 implies analysts expect significant future earnings growth.
EXAS appears fairly valued to slightly overvalued based on current metrics. It trades at a significant premium on a Price-to-Sales basis (5.9) and a high forward P/E (55.2), which is justified by its high growth rate but leaves no room for error. The valuation is not egregious given the 23% YoY revenue growth and improving margins, but it is not demonstrably cheap either, suggesting it is priced for perfection.
At the current price near its 52-week high, EXAS is a Hold, not a clear Buy. The company's fundamentals are improving dramatically with 23% revenue growth and positive free cash flow. However, the stock's ~97% surge over six months and premium valuation (PS ratio 5.9, forward P/E 55.2) suggest much of this good news is already priced in, limiting near-term upside potential for new investors.
EXAS is more suitable for long-term investors who can tolerate volatility and are confident in the company's multi-year growth story in cancer diagnostics. The short-term outlook is clouded by the stock's overbought technical condition and full valuation. Long-term holders can look past near-term price fluctuations to the underlying fundamental improvement, but short-term traders face a challenging risk/reward setup after the parabolic move.